A Model of Hematopoietic Bone Marrow Apoptosis During Growth Factor Deprivation in Combination with a Cytokine

Overview

Journal Theor Biol Med Model

Publisher Biomed Central

Date 2018 Jun 22

PMID 29925399

Authors

Christina L Mouser

Eliana S Antoniou

Evros K Vassiliou

Affiliations

Soon will be listed here.

Abstract

Background: The process by which blood cells are formed is referred to as hematopoiesis. This process involves a complex sequence of phases that blood cells must complete. During hematopoiesis, a small fraction of cells undergo cell death. Causes of cell death are dependent upon various factors; one such factor being growth factor deprivation.

Methods: In this paper, a mathematical model of hematopoiesis during growth factor deprivation is presented. The model consists of a set of three coupled differential delay equations. Phase plane and linear stability analysis are performed in order to locate and determine stability of fixed points. Numerical simulations of the governing equations are run and provide a visual display of the behavior of the stem cell population undergoing growth factor deprivation. In addition, the effect of cytokine administration is incorporated in the model in an effort to understand how cytokine administration can offset the negative effects of apoptosis caused by growth factor deprivation.

Conclusions: The model produces qualitatively similar results to that observed during serum deprivation. The model captures apoptosis levels of cells at different time points. Additionally, it is shown that cytokine administration stabilizes the stem cell count.

References

Ogunshola O, Bogdanova A . Epo and non-hematopoietic cells: what do we know?. Methods Mol Biol. 2013; 982:13-41. DOI: 10.1007/978-1-62703-308-4_2. View

Berlier J, Rigutto S, Dalla Valle A, Lechanteur J, Soyfoo M, Gangji V . Adenosine triphosphate prevents serum deprivation-induced apoptosis in human mesenchymal stem cells via activation of the MAPK signaling pathways. Stem Cells. 2014; 33(1):211-8. DOI: 10.1002/stem.1831. View

Bryder D, Jacobsen S . Interleukin-3 supports expansion of long-term multilineage repopulating activity after multiple stem cell divisions in vitro. Blood. 2000; 96(5):1748-55. View

Bernard S, Belair J, Mackey M . Bifurcations in a white-blood-cell production model. C R Biol. 2004; 327(3):201-10. DOI: 10.1016/j.crvi.2003.05.005. View

Bernard S, Belair J, Mackey M . Oscillations in cyclical neutropenia: new evidence based on mathematical modeling. J Theor Biol. 2003; 223(3):283-98. DOI: 10.1016/s0022-5193(03)00090-0. View

van Engeland M, Nieland L, Ramaekers F, Schutte B, Reutelingsperger C . Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry. 1998; 31(1):1-9. DOI: 10.1002/(sici)1097-0320(19980101)31:1<1::aid-cyto1>3.0.co;2-r. View

Shah A, Smogorzewska E, Hannum C, Crooks G . Flt3 ligand induces proliferation of quiescent human bone marrow CD34+CD38- cells and maintains progenitor cells in vitro. Blood. 1996; 87(9):3563-70. View

Zhang C, Lodish H . Cytokines regulating hematopoietic stem cell function. Curr Opin Hematol. 2008; 15(4):307-11. PMC: 2677548. DOI: 10.1097/MOH.0b013e3283007db5. View

Lindvall O, Kokaia Z . Stem cells in human neurodegenerative disorders--time for clinical translation?. J Clin Invest. 2010; 120(1):29-40. PMC: 2798697. DOI: 10.1172/JCI40543. View

10.

Duhrsen U, Villeval J, Boyd J, Kannourakis G, Morstyn G, Metcalf D . Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood. 1988; 72(6):2074-81. View

11.

Mackey M . Cell kinetic status of haematopoietic stem cells. Cell Prolif. 2001; 34(2):71-83. PMC: 6495991. DOI: 10.1046/j.1365-2184.2001.00195.x. View

12.

Antoniou E, Mouser C, Rosar M, Tadros J, Vassiliou E . Hematopoietic stem cell proliferation modeling under the influence of hematopoietic-inducing agent. Shock. 2009; 32(5):471-7. DOI: 10.1097/SHK.0b013e3181a1a05f. View

13.

Bendall L, Bradstock K . G-CSF: From granulopoietic stimulant to bone marrow stem cell mobilizing agent. Cytokine Growth Factor Rev. 2014; 25(4):355-67. DOI: 10.1016/j.cytogfr.2014.07.011. View

14.

Lotem J, Sachs L . Cytokine control of developmental programs in normal hematopoiesis and leukemia. Oncogene. 2002; 21(21):3284-94. DOI: 10.1038/sj.onc.1205319. View

15.

Mouser C, Antoniou E, Tadros J, Vassiliou E . A model of hematopoietic stem cell proliferation under the influence of a chemotherapeutic agent in combination with a hematopoietic inducing agent. Theor Biol Med Model. 2014; 11:4. PMC: 3899742. DOI: 10.1186/1742-4682-11-4. View

16.

Birbrair A, Frenette P . Niche heterogeneity in the bone marrow. Ann N Y Acad Sci. 2016; 1370(1):82-96. PMC: 4938003. DOI: 10.1111/nyas.13016. View

17.

Brugger W, Mocklin W, Heimfeld S, Berenson R, Mertelsmann R, Kanz L . Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin. Blood. 1993; 81(10):2579-84. View

18.

Zhu W, Chen J, Cong X, Hu S, Chen X . Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells. Stem Cells. 2005; 24(2):416-25. DOI: 10.1634/stemcells.2005-0121. View

19.

Das M, Chatterjee S, Basak P, Das P, Pereira J, Dutta R . The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model. J Stem Cells. 2011; 5(2):49-64. View

20.

Lacy P . Editorial: secretion of cytokines and chemokines by innate immune cells. Front Immunol. 2015; 6:190. PMC: 4406090. DOI: 10.3389/fimmu.2015.00190. View